SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray is trending amid speculation that the Trump administration may be considering easing federal marijuana restrictions, potentially reclassifying it as a Schedule III drug. The community is actively discussing target prices and potential short squeezes, while also speculating on how Tilray and other cannabis stocks will react to the potential policy change.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and the FC SAN business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom's stock is trending due to analyst target price updates and discussions around a recently revealed $10 billion custom AI chip order from Anthropic, now followed by an additional $11 billion order. While some see amazing earnings, others worry about gross margins and question a sky-high valuation; the community is closely watching for a potential dip-buying opportunity.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon is trending following a Q3 earnings beat, a raised full-year guidance, and the announcement of a CEO succession plan and a buyback program. The community is discussing the potential for analyst upgrades and the impact of international business, particularly in China, on the company's future growth. Some traders are noting overnight gains and anticipating a continued run, while others express concerns about overnight crashes and are eyeing the $225-$240 range.

Mawson Infrastructure Group, Inc. engages in the provision of digital asset infrastructure services. The company was founded on February 10, 2012 and is headquartered in Midland, PA.

Mawson Infrastructure Group Inc

MIGI is trending due to a volatile trading session following a reverse stock split and recent ATM offering announcement, with community members debating whether the price action signals a pump and dump scheme or a genuine opportunity. Discussions revolve around the company's market cap requirements for Nasdaq compliance and speculation about potential news catalysts. The stock's low float and high short interest are also contributing to the intense speculation and trading activity.

Yee is a community based memecoin with one mission: to fight Pepe again. Made to honor the iconic meme rivalry we all know and love.  The Yee Legend  [Filed by: Yee’s Archivist & Legal Representative]  There’s something the meme world refuses to talk about: Pepe the Frog stole Yee the Dino’s entire launch plan.  Yee had been preparing for his comeback for months, but Pepe launched two weeks earlier, hijacking Yee’s concept and selling it as his own.  The charges? Meme theft, intellectual forgery, and historical erasure.  Yee’s official contract was filed in April 2023, right after Pepe’s surprise drop. This wasn’t timing—it was theft. The archives are about to open, and history is about to be corrected

Yee Token

$YEE is gaining traction, fueled by community enthusiasm and increasing buying pressure. Discussions highlight its potential within the Ethereum ecosystem, with some drawing comparisons to earlier memecoins and touting a possible 'prophecy' narrative. The community rallies around $YEE's momentum, anticipating further upward movement.

Knightscope, Inc. engages in the provision and development of security technology solutions. Its product portfolio includes the K1 stationary machine, the K3 indoor machine, the K5 outdoor machine, and the K7 multi-terrain four-wheel vehicle. Its machines patrol client sites without the need for remote control to provide a visible, force multiplying, physical security presence to help protect assets, monitor changes in the area, and deter crime. The company was founded by William Santana Li and Stacy Dean Stephens on April 4, 2013 and is headquartered in Sunnyvale, CA.

Knightscope Inc - Ordinary Shares - Class A

Knightscope is trending due to a recently announced partnership with Palantir, generating excitement about potential expansion into the U.S. federal market. Community discussions revolve around the long-term potential of KSCP in the robotics and security sector, with some emphasizing its low market cap and others expressing skepticism based on past performance and dilution concerns. Some investors believe the partnership with Palantir could lead to significant growth and government contracts, while others are wary of pump-and-dump schemes.

Hycroft Mining Holding Corp. engages in the exploration, mining, and development of gold and silver properties. The company was founded on August 28, 2017 and is headquartered in Winnemucca, NV.

Hycroft Mining Holding Corporation - Ordinary Shares - Class A

HYMC is trending as precious metals prices rise, with silver nearing all-time highs, leading to community excitement around the potential value of Hycroft's silver deposits. Investor Eric Sprott's increased stake in the company is adding to the positive sentiment, while discussions about AMC's previous involvement and potential future catalysts like drill results also fuel the conversation.

RH operates as a holding company which operates the business through its subsidiary Restoration Hardware, Inc. It offers furniture, lighting, textiles, bath ware, decor, outdoor and garden, as well as baby and child products. The company operates an integrated business with multiple channels of distribution including galleries, source books and websites. The company was founded by Stephen J. Gordon in 1980 and is headquartered in Corte Madera, CA.

RH - Ordinary Shares - Class A

Restoration Hardware

RH is trending as investors digest recent earnings and forward guidance, with community chatter focused on the CEO's commentary and the potential impact of tariffs. Some believe RH is undervalued and poised for a short squeeze, while others worry about the company's debt and exposure to the housing market.

Spirit Realty Capital is a Real Estate Investment Trust (REIT) company located in Scottsdale, Arizona.  Spirit Realty Capital was formed in 2003 to acquire single tenant, “operationally essential” real estate, which refers to generally free-standing, commercial real estate facilities where our tenants conduct retail, service or distribution activities that are essential to the generation of their sales and profits.

Realty Income Corp.

Realty Income ($O) is trending as investors weigh its potential amid fluctuating interest rate expectations and recent analyst rating adjustments. Community discussions revolve around its dividend reliability, global expansion, and comparison to peers like Digital Realty ($DLR) and Agree Realty ($ADC). Some are concerned about its growth prospects and exposure to retail tenants, while others see it as a stable income play for long-term investors, especially with potential rate cuts on the horizon.

Assemble’s AI agent, News3(NS3), was developed with the goal of revolutionizing Web 3.0 journalism. NS3 delivers crypto and global economic trends quickly and clearly, and leverages advanced AI reasoning capabilities to analyze these trends, enabling market participants to make data-driven decisions. In particular, NS3 utilizes OpenAI’s latest reasoning model as its core engine to analyze crypto and economic trends, providing a range of insights including market psychology, past case analysis, future predictions, ripple effects, and investment strategies in 12 languages.

Assemble Protocol

Assemble Protocol ($ASM) is trending amid community excitement and speculation, with some users pointing to AI developments as a catalyst. Community members are actively discussing potential partnerships and bullish technical indicators, with some hoping for a significant price increase. However, there are also concerns about past performance and potential market manipulation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Terns Pharmaceuticals (NASDAQ:TERN) Price Target Raised to $57.00

Citizens Jmp boosted their price objective on Terns Pharmaceuticals from $35.00 to $57.00 and gave the company a "market outperform" rating in a report on Thursday...

Research Analysts Set Expectations for TERN FY2027 Earnings

Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) - Analysts at HC Wainwright raised their FY2027 earnings per share (EPS) estimates for shares of Terns Pharmaceuticals in a research note...

Pharmaceutical Stocks To Follow Today - December 10th

Eli Lilly and Company, AbbVie, Pfizer, Novo Nordisk A/S, and Terns Pharmaceuticals are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical...

Terns Pharmaceuticals (NASDAQ:TERN) Sees Large Volume Increase - Here's Why

Terns Pharmaceuticals (NASDAQ:TERN) Sees Large Volume Increase - Still a Buy...

<ul class="summary-bullets"><li>Terns shares jumped after new Phase 1 data showed strong response rates and a continued favorable safety profile for TERN-701.</li><li>Updated results showed high 24-week molecular responses across doses with no loss of response and no dose-limiting toxicities.</li><li>The company said the findings support Phase 2 advancement, with deep responses seen even in patients previously failing multiple therapies.</li></ul>Terns Pharmaceuticals (TERN) shares jumped over 40% on Monday after the company reported additional positive Phase 1 results for its investigational chronic myeloid leukemia (CML) therapy TERN-701 at the 67th American Society of Hematology Annual Meeting.The biotech company said updated data from the ongoing CARDINAL trial showed a 64% major molecular response (MMR) rate by 24 weeks across all efficacy-evaluable patients, with a 75% MMR rate among those receiving doses above 320 mg once daily.&nbsp;The company said the treatment continued to show an encouraging safety and tolerability profile with longer exposure.<h2 class="st-heading-2">Terns Sets Phase 2 Doses&nbsp;</h2>CEO Amy Burroughs said the higher MMR rate at doses of 320 mg and 500 mg supports selection of those levels as recommended Phase 2 doses. She said study enrollment has surpassed 85 patients, enabling further progression into dose-expansion and pivotal studies.Chief Medical Officer Emil Kuriakose said the data include response achievements in patients who had previously experienced lack of efficacy on drugs such as Asciminib, Ponatinib and other tyrosine kinase inhibitors. He said the updated findings show deep molecular responses (DMR) at 24 weeks and a continued favorable safety profile across doses.<h2 class="st-heading-2">Strong 24-Week Response Rates</h2>As of the Sept. 13 cutoff, 63 patients had been enrolled across doses ranging from 160 mg to 500 mg. Among 38 efficacy-evaluable patients, the overall MMR rate by 24 weeks was 74%. No patients had lost MMR at the time of analysis.The company said the study population reflected heavily pretreated, refractory disease, including a median of three prior tyrosine kinase inhibitors (TKIs) and high rates of lack of efficacy to previous therapy.Safety data showed that 87% of patients remained on treatment, with no dose-limiting toxicities observed and no maximum tolerated dose reached. Most treatment-emergent adverse events were low grade, and rates of cytopenias were generally under 10%.<h2 class="st-heading-2">Responses At Higher Doses</h2>Among patients treated at doses of 320 mg or higher, the company reported an 80% overall MMR rate by 24 weeks in the efficacy-evaluable population. Deep molecular responses were observed across a wide range of baseline transcript levels.<h2 class="st-heading-2">Stocktwits Traders Cheer Momentum</h2>On Stocktwits, retail sentiment for Terns was ‘bullish’ amid ‘low’ message volume.<figure class="image"><img style="aspect-ratio:984/147;" src="https://news.stocktwits-cdn.com/terns_ss_png_43b9b42eb3.webp" alt="terns ss.png" width="984" height="147"><figcaption>TERN sentiment and message volume as of December 8| Source: Stocktwits</figcaption></figure>One user said, “congrats!&nbsp; Bio market is starting to have some movers. Good to see!”<stembedurl>https://stocktwits.com/Hard6and8/message/638531110</stembedurl>Another user urged investors to “buy it up.”<stembedurl>https://stocktwits.com/Whiskeyunderthebed/message/638530725</stembedurl><a href="https://stocktwits.com/symbol/TERN">Tern’s stock</a> has surged 620% so far this year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Tern's stock (TERN) has surged 489% so far in 2025. (Photo credit: Getty Images)

Terns Pharmaceuticals Stock Soars After Leukemia Drug Delivers Big Early Responses In Tough-To-Treat Patients

New Phase 1 data showed strong response rates and a favorable safety profile for its experimental leukemia drug TERN-701.

Equity

Terns Pharmaceuticals (NASDAQ:TERN) Shares Gap Up - Time to Buy?

Terns Pharmaceuticals (NASDAQ:TERN) Shares Gap Up - Should You Buy...

Terns Pharmaceuticals (NASDAQ:TERN) Stock Price Up 5.5% - Here's Why

Terns Pharmaceuticals (NASDAQ:TERN) Stock Price Up 5.5% - Still a Buy...

Terns Pharmaceuticals (NASDAQ:TERN) Reaches New 1-Year High - Still a Buy?

Terns Pharmaceuticals (NASDAQ:TERN) Sets New 52-Week High - Should You Buy...

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives Consensus Rating of "Moderate Buy" from Analysts

Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) has received a consensus rating of "Moderate Buy" from the twelve brokerages that are presently covering the stock, MarketBeat.com reports...

Terns Pharmaceuticals (NASDAQ:TERN) Stock Price Down 5.7% - Time to Sell?

Terns Pharmaceuticals (NASDAQ:TERN) Shares Down 5.7% - Time to Sell...

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.

Terns Pharmaceuticals Inc

Bullish: S&P grinds higher

Choppy but up: buy dips

Sideways: fade the move

Bearish: this rally falls off

The Federal Reserve just announced a 0.25 percentage point interest rate cut at its December 10, 2025 meeting.​ Share your outlook on how the latest Federal Reserve interest rate cut will impact stocks and the S&P 500 over the next month.

How do you think today’s Fed rate cut impacts stocks over the next month?

TERN
Terns Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest TERN News

TERNTerns Pharmaceuticals Inc